Results 1 to 10 of about 77,929 (279)

Factors affecting employment in Japanese patients with ankylosing spondylitis (AS) [PDF]

BMC Rheumatology
Background Ankylosing spondylitis (AS) often affects individuals during their most productive working years. However, few studies have investigated factors influencing employment in Japanese AS patients.
Hoshiko Furusawa, Kurisu Tada, Eri Hayashi, Hisashi Inoue, Shigeto Kobayashi, Ken Yamaji, Naoto Tamura   +6 more
doaj   +2 more sources

The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study [PDF]

, 2012
INTRODUCTION: The aim of this study was to investigate the effect of three years of tumor necrosis factor-alpha (TNF-alpha) blocking therapy on bone turnover as well as to analyze the predictive value of early changes in bone turnover markers (BTM) for ...
Arends, S., Bos, R., Brouwer, E., Groen, H., Houtman, P.M., Kallenberg, C.G., Leijsma, M.K., Spoorenberg, A., van der Veer, E.   +8 more
core   +17 more sources

Relationship between smoking, clinical, inflammatory, and radiographic parameters in patients with ankylosing spondylitis

Egyptian Rheumatology and Rehabilitation, 2021
Background Ankylosing spondylitis (AS) is an autoimmune multisystemic disease that attacks the spine, sacroiliacs, and often causes asymmetrical peripheral oligoarthritis. It results from the interaction between the genetic factors mainly Human Leukocyte
Hanan M. Farouk, Maryam A. Abdel-Rahman, Rasha Mohamad Hassan   +2 more
doaj   +1 more source

Ankylosing spondylitis: how does it affect the quality of life?

Liječnički vjesnik, 2023
Ankylosing spondylitis is a progressive and debilitating disease known to immensely affect the quality of life and frequently cause disability. There are several instruments that measure this effect, such as Bath Ankylosing Spondylitis Disease Activity ...
Eva Perak, Valerija Plečko, Antonija Gračanin, Ana Gudelj Gračanin   +3 more
doaj   +1 more source

A new and spontaneous animal model for ankylosing spondylitis is found in cynomolgus monkeys

Arthritis Research & Therapy, 2022
Background Ankylosing spondylitis is a progressive, disabling joint disease that affects millions worldwide. Given its unclear etiology, studies of ankylosing spondylitis relied heavily on drug-induced or transgenic rodent models which retain only ...
Huanhuan Jia, Meili Chen, Yanzhen Cai, Xiaoling Luo, Gang Hou, Yongfeng Li, Chunmei Cai, Jun Chen, Qingnan Li, Kai-Kei Miu, Sin-Hang Fung, Zhangting Wang, Ren Huang, Huiyong Shen, Li Lu   +14 more
doaj   +1 more source

Increased Risk of Common Orthopedic Surgeries for Patients with Rheumatic Diseases in Taiwan

Medicina, 2022
Background and Objectives: Rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, and systemic lupus erythematosus (SLE), are characterized by chronic arthritis or spondyloarthritis, which can lead to joint and spine ...
Min-Chih Hsieh, Malcolm Koo, Chia-Wen Hsu, Ming-Chi Lu   +3 more
doaj   +1 more source

Ankylosing Spondylitis and the Risk of Lung Cancer: A Meta-Analysis and Mendelian Randomization

Frontiers in Genetics, 2022
Background: It remains uncertain whether ankylosing spondylitis is associated with an increased risk of lung cancer.Methods: We conducted a meta-analysis to comprehensively evaluate the correlation between ankylosing spondylitis and lung cancer based on ...
Yiyuan Ao, Yiyuan Ao, Yaokai Wen, Yaokai Wen, Yutian Li, Yutian Li, Haoxin Peng, Haoxin Peng, Xiangrong Wu, Xiangrong Wu, Zhufeng Wang, Yu Jiang, Yu Jiang, Yuechun Lin, Yuechun Lin, Shuben Li   +15 more
doaj   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

A comparison of three methods to generate a conceptual understanding of a disease based on the patients’ perspective

Journal of Patient-Reported Outcomes, 2017
Background The Food and Drug Administration patient-reported outcome (PRO) guidance provides standards for PRO development, but these standards bring scientific and logistical challenges which can result in a lengthy and expensive instrument development ...
Louise Humphrey, Thomas Willgoss, Andrew Trigg, Stephanie Meysner, Mary Kane, Sally Dickinson, Helen Kitchen   +6 more
doaj   +1 more source

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis : 48-week results from the EMBARK study [PDF]

, 2015
Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).
Bonin, Randi, Braun, Jürgen, Bukowski, Jack F, Citera, Gustavo, Dougados, Maxime, Jones, Heather, Kotak, Sameer, Logeart, Isabelle, Maksymowych, Walter P, Marshall, Lisa, Pedersen, Ron, Sieper, Joachim, Van den Bosch, Filip, van der Heijde, Désirée, Vlahos, Bonnie, Wajdula, Joseph   +15 more
core   +1 more source